HLA-DQB103:01 and HLA-DQA105:05 as key genetic determinants of infliximab response and immunogenicity in Japanese patients with inflammatory bowel disease.

J Gastroenterol · 2026 · PMC13157412 · PMID 41652206

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.1400

boldest claim

The sentences

showed a trendp = 0.06so close (0.05 < p ≤ 0.1)

HLA-DQB1*03:01 was associated with higher ADA levels ( p = 3.23E-03) and showed a trend toward increased ADA positivity ( p = 0.06).

also in 53,322 other papers

did not reach statistical significancep = 0.14not close (p > 0.1)

For patients with UC, univariate analysis showed that although the association did not reach statistical significance (HR = 1.81, p = 0.14), HLA-DQA1*05 carriers tended to have a worse prognosis compared with non-carriers.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

HLA-DQB1*03:01 and HLA-DQA1*05:05 as key genetic determinants of infliximab response and immunogenicity in Japanese patients with inflammatory bowel disease.

The sentences

HLA-DQB103:01 and HLA-DQA105:05 as key genetic determinants of infliximab response and immunogenicity in Japanese patients with inflammatory bowel disease.